-
Media Room Article
Cancer Research Institute Appoints New Chief Development and Operations Officers to Drive Growth and Innovation
NEW YORK, NY — The Cancer Research Institute (CRI) is pleased to announce the addition of two… -
Media Room Article
Immunotherapy Titans to Be Honored for Scientific Excellence at CRI’s 2024 Annual Awards Gala
NEW YORK—October 8, 2024—The Cancer Research Institute (CRI) will celebrate groundbreaking achievements in immunotherapy at its 2024… -
Media Room Article
The Cancer Research Institute and the Kidney Cancer Association Announce a Collaboration to Co-Fund Kidney Cancer Immunotherapy Research
NEW YORK, NY and HOUSTON, TX — The Cancer Research Institute (CRI) is proud to announce a… -
Media Room Article
Cancer Research Institute (CRI) Appoints Alicia Zhou, PhD, as Chief Executive Officer to Advance Next Generation of Cancer Immunotherapy Science and Innovation
NEW YORK, NY — The Cancer Research Institute (CRI), the preeminent nonprofit organization focused on advancing breakthroughs… -
Media Room Article
Global Experts Converge at CICON24 to Unveil Groundbreaking Advances in Cancer Immunotherapy, September 8-11, 2024 at National Harbor, MD
NATIONAL HARBOR, MD – The Cancer Research Institute (CRI) and the European Network for Cancer Immunotherapy (ENCI)… -
Media Room Article
The 2024 Impact Report of the Cancer Research Institute
Executive Summary Since our founding in 1953, the Cancer Research Institute (CRI) has been at the forefront… -
Media Room Article
Cancer Research Institute Awards Over $22 Million in Grants to Fuel Immunotherapy Innovations
NEW YORK – August 8, 2024 — As the leading nonprofit organization committed to revolutionizing cancer treatment… -
Media Room Article
Cancer Research Institute Announces New Lloyd J. Old STARs Class
New York, NY – August 5, 2024 – The Cancer Research Institute (CRI) proudly announces the newest… -
Media Room Article
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics’ ENB-003 for the Treatment of Ovarian Cancer
REDWOOD CITY, Calif., May 8, 2024 — Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the…
